Sitafloxacin speeds recovery in nontuberculous mycobacterial lung disease

Nontuberculous mycobacterial (NTM) pulmonary disease is a growing clinical problem that can be difficult to treat and monitor. To learn whether adding a specific antibiotic could improve outcomes, a multi-center, retrospective cohort study was led by corresponding author Yiru Zhang that reviewed patient records from 2021 to 2024. The study included 149 adults with confirmed NTM pulmonary disease; 73 patients received sitafloxacin-containing regimens for at least three months (the sitafloxacin group) and 76 served as a control group receiving non-sitafloxacin therapy. Patients with extrapulmonary or disseminated NTM, HIV, active tuberculosis, or incomplete clinical data were excluded. The investigators focused on clear, measurable outcomes: whether patients converted from positive to negative cultures from sputum or BALF, how long that conversion took, and whether chest imaging showed improvement. They also tracked adverse events (AEs) to assess safety. By comparing these two groups, the team aimed to determine if sitafloxacin could meaningfully speed microbiological clearance and promote radiographic healing without adding safety concerns.

This retrospective cohort study directly compared sitafloxacin-containing regimens to non-sitafloxacin therapy in adults with NTM pulmonary disease. The primary endpoints were sputum/BALF culture conversion rate and time to culture conversion; the secondary endpoints were radiographic improvement and adverse events (AEs). In the 73 patients treated with sitafloxacin, the culture conversion rate was 53.8% versus 22.1% in the 76-patient control group (P < 0.001). The sitafloxacin group also achieved faster clearance, with a median time to culture conversion of 195 days compared with 292 days in the control group (P < 0.001). Radiographic improvement on imaging was observed more often in the sitafloxacin group (54.5% vs. 36.1%, P = 0.046). Safety monitoring showed that the sitafloxacin group did not experience significantly more adverse events than the control group. These results summarize the key measured benefits and the safety profile reported in the study.

The findings reported by Yiru Zhang suggest that sitafloxacin-based regimens can accelerate microbiological clearance and increase the chance of radiographic improvement in people with NTM pulmonary disease, while maintaining a comparable safety profile to non-sitafloxacin therapies. For clinicians and patients this could mean a treatment option that more reliably leads to negative sputum/BALF cultures and visible healing on chest imaging in a shorter time frame. Because the study is retrospective, the results describe real-world outcomes across multiple centers from 2021 to 2024 rather than the controlled environment of a randomized trial; however, the magnitude of the differences in conversion rates and time to conversion supports considering sitafloxacin when designing treatment plans. Ultimately, the study positions sitafloxacin as a viable drug for improved treatment of NTM infections and provides a basis for further prospective research and clinical consideration.